The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.
Over their lifetimes, these top-selling medicines have generated between $35 billion and $148 billion in sales.
AbbVie, Amgen, and Gilead Sciences make the list of top biotech dividend stocks. But which is the best of all?
Goldman Sachs has "conviction" this is the drug stock to buy.
AbbVie executives answered questions about the biotech's future at the Cowen healthcare conference.
Which high-growth cloud play is a better buy at current prices?
If you're new to biotech investing, these are three companies you need to know.
New sales guidance for Gilead Sciences suggests that the company's struggles could continue to disappoint investors this year.
Which clinical-stage biotech stock wins in a head-to-head match-up between Agenus and Alnylam?
Data from a competitor gives investors hope that the company's drug will have a larger potential market.